SaNOtize Research & Development Corp., a Vancouver, BC, Canada-based anti-infective-focused therapeutics company, raised $24m in Series B funding.
The round was co-led by Horizons Ventures and OurCrowd, with participation from Agricultural Bank of China International. Frances Kang, Portfolio Curator, Horizons Ventures, who was recently appointed to the SaNOtize board of directors.
The company intends to use the funds to advance its nitric oxide-based therapeutics pipeline, including its ongoing global Phase 3 nitric oxide nasal spray (NONS™) prevention clinical study with plans to recruit up to 3,000 participants in Canada and Sri Lanka.
Founded in 2017 by Gilly Regev, PhD, Co-Founder and CEO, and Chris Miller, PhD, Chief Scientific Officer and Co-Founder, SaNOtize Research & Development Corp. is a pharmaceutical company commercializing the multi-faceted antimicrobial properties of a liquid producing nitric oxide.
Its Nitric Oxide Nasal Spray (NONS™) has been clinically shown to treat COVID-19 in high-risk adult patients and to prevent infections when used immediately after known exposure to SARS-CoV-2.
NONS is currently sold as a medical device under the brand name VirXTM in Thailand, Hong Kong, and Singapore and as a medical device under the brand name of enovid™ in Indonesia, Israel, and Bahrain. In India, NONS received an emergency use approval by the Central Drugs Standard Control Organization (CDSCO) for treatment of adult patients with COVID-19 who have a risk of progression of the disease. It is registered as a Class I medical device and under CE mark in the European Union. While NONS is not yet approved for sale in Canada or USA, SaNOtize is in discussions with regulatory authorities in both countries.
FinSMEs
24/08/2022